 HYDERABAD, India MISSISSAUGA, Ontario--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid lenalidomide capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada. Our launch of Reddy 